5 February 2020 - Commercial distribution of Vyondys 53 in the U.S. is currently underway.
Orsini Pharmaceutical Services announced today that it has been selected as one of two limited distribution partners for Vyondys 53 (golodirsen).
The newly approved product is indicated for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 53 skipping. Vyondys 53 is manufactured and marketed by Sarepta Therapeutics, which is headquartered in Cambridge, Mass.